Aa
NOV-205 (Molyxan) any new news on this one?
What has happened with Novelos product Molyxan? Any news on the development?
According to www.hepb.org drug watch section it is a drug already approved in Russia, but we know nothing yet regarding its efficacy(%hbsag loss,%hbvdna und). Maybe some Russian members know more about it.
I think this is another interesting drug that is being overlooked for possible use as a combo with antiviral like ETV or Tenofovir.
Some clinics in Ukraine use it with antiviral + interferon or zadaxin.
I think that is is another smart strategy at approaching HBV. But again there with lack of funding it is just mostly experiments by real maverick hepatologists that want to come with their way of a better treatment strategy. This is what they could start doing here in the US with better diagnostic equipment available to take it one step further..
===================================================
Molixan® corrects the Th1/Th2 cytokine production ratio with the T-cell group with prevailing activation of Th1-cells due to endogenous production stimulation of IL-2 and IL-12 providing stable cell-mediated immune response including functional activity of resident liver macrophages (Kupffer's cells).
Antiviral immunity stimulation and the HBV and HCV replicative activity inhibition due to induction of apoptosis in the virus-infected cells
Cytolytic syndrome cessation and reduction of pathologic morphological signs in liver
Normalization of serological and biochemical indices
Serum HBsAg persistency cessation
Prevailing activation of the T-cell immunity along with regulable stimulation of the resident macrophage functions
Regulation of serum levels of anti-inflammatory cytokines
Inhibition of liver fibrogenesis
==================================================
Some clinics in Ukraine use it with antiviral + interferon or zadaxin.
I think that is is another smart strategy at approaching HBV. But again there with lack of funding it is just mostly experiments by real maverick hepatologists that want to come with their way of a better treatment strategy. This is what they could start doing here in the US with better diagnostic equipment available to take it one step further..
===================================================
Molixan® corrects the Th1/Th2 cytokine production ratio with the T-cell group with prevailing activation of Th1-cells due to endogenous production stimulation of IL-2 and IL-12 providing stable cell-mediated immune response including functional activity of resident liver macrophages (Kupffer's cells).
Antiviral immunity stimulation and the HBV and HCV replicative activity inhibition due to induction of apoptosis in the virus-infected cells
Cytolytic syndrome cessation and reduction of pathologic morphological signs in liver
Normalization of serological and biochemical indices
Serum HBsAg persistency cessation
Prevailing activation of the T-cell immunity along with regulable stimulation of the resident macrophage functions
Regulation of serum levels of anti-inflammatory cytokines
Inhibition of liver fibrogenesis
==================================================
MOLIXAN®
1% and 3% SOLUTION OF MOLIXAN FOR INJECTIONS
Trade patented drug name: Molixan®.
Chemical name: organic salt of bis-glycine-L-cysteinyl-bis-(g -L-glutamate)•9-b -D-ribofuranozilhypoxanthine.
Drug form: 1% and 3% solution for injections.
Formulation: 1 ml of the solution comprises 10 or 30 mg of the organic salt of bis-glycine-L-cysteinyl-bis-(g -L-glutamate) and 9-b -D-ribofuranozilhypoxanthine.
DESCRIPTIONS
Transparent colorless or slightly greenish odorless liquid.
PHARMACOLOGICAL PROPERTIES
Pharmacotherapeutic group:
Hepatoprotective agent with immunomodulating and antiviral activity.
Pharmacodynamics:
Molixan® possesses unique biological and pharmacological effects due to the following:
Regulation of thiol-disulfide metabolism in hepatocytes and immune cells.
Regulation of endogenous production of cytokines by liver macrophages including IFN a and g determining the drug immunorehabilitating and antiviral activity.
Pronounced differentiated impact on the normal and virus-transformed cells.
Inhibition of ATP-ase/helicase activity of NS3 HCV.
Being the analogue of key cell metabolites the active principles of the composite therapeutics, Molixan®, have high bioavailability, therefore, being introduced into biological media they instantly translocate into target cells inducing cascade mechanism of biochemical reactions regulating cell metabolism, proliferation, differentiation and apoptosis forming a wide range of immunomodulating and hepatoprotective effects. The differentiated action on unimpaired hepatocytes and resident macrophages (stimulation of metabolism, proliferation, and differentiation) and virus-infected cells (induction of apoptosis mechanism including due to expression of FasAg-CD95+ and Ras-signaling and p53-dependent apoptotic pathways in the virus-infected hepatocytes) is the basis for the mechanisms inhibiting the HBV and HCV replicative activity.
The antiviral Molixan® efficacy on HVC is determined by its capacity to inhibit the NS3 HCV ATP-ase/helicase activity hindering chronization and facilitating the viral elimination.
Molixan® corrects the Th1/Th2 cytokine production ratio with the T-cell group with prevailing activation of Th1-cells due to endogenous production stimulation of IL-2 and IL-12 providing stable cell-mediated immune response including functional activity of resident liver macrophages (Kupffer's cells).
Thus, Molixan® possesses antiviral, immunomodulating and hepatoprotective (inhibition of post-hepatitis fibrogenesis) effects that determines its medical indications.
Pharmacokinetics:
The Molixan® substance is an organic salt where counter-ions are endogenous substances (oxidized glutathione and inosine). The natural origin of the drug determinates its metabolic particularities by cell enzyme systems. According to preclinical studies the Molixan® pharmacokinetics after intravenous dosing of 10 mg/kg is described using double-part model with the following indices (as per oxidized glutathione): maximal plasma concentration - 170-180 m g/ml; elimination constant - 0.085 min-1; bioavailability - 450-500 min.m g/ml; total clearance - 20 ml/kg/min; average retention rate - 6-8 min. Being a natural product having peptide and purine constituents Molixan® is metabolized in organs and tissues to amino acids and derivatives of purine bases and it is eliminated via kidneys.
MOLIXAN® ADMINISTRATION TO THE PATIENTS WITH VIRAL HEPATITIS B AND C ENSURES THE FOLLOWING:
Antiviral immunity stimulation and the HBV and HCV replicative activity inhibition due to induction of apoptosis in the virus-infected cells
Cytolytic syndrome cessation and reduction of pathologic morphological signs in liver
Normalization of serological and biochemical indices
Serum HBsAg persistency cessation
Prevailing activation of the T-cell immunity along with regulable stimulation of the resident macrophage functions
Regulation of serum levels of anti-inflammatory cytokines
Inhibition of liver fibrogenesis
INDICATIONS
Therapy
Acute and chronic viral hepatitis B, C and mixed forms
Drug-induced hepatitis (including cases after tuberculous and cancer chemotherapy)
Alcohol-induced liver disease
Toxic hepatitis
Fat liver degeneration of various origin
Prevention
Liver cirrhosis and hepatocellular carcinoma
CONTRAINDICATIONS
The drug introduction is contraindicated only in cases of individual intolerance.
ADVERSE EFFECTS
Adverse effects were not noted. However, individual drug intolerance is possible. In that case the drug should be canceled and consulting with an attending physician is necessary.
DRUG FORM
1% and 3% solution for injections in 1-ml and 2-ml ampoules. Packages - 5 or 10 ampoules
STORAGE CONDITIONS
The drug should be stored in a shadowed place at not higher than +250C.
The drug shall not be used after expiration date.
The drug should be stored in a place inaccessible for children.
SHELF LIFE
2 years.
MANUFACTURE DETAILS
Pharma BAM Spb, Ltd.
1% and 3% SOLUTION OF MOLIXAN FOR INJECTIONS
Trade patented drug name: Molixan®.
Chemical name: organic salt of bis-glycine-L-cysteinyl-bis-(g -L-glutamate)•9-b -D-ribofuranozilhypoxanthine.
Drug form: 1% and 3% solution for injections.
Formulation: 1 ml of the solution comprises 10 or 30 mg of the organic salt of bis-glycine-L-cysteinyl-bis-(g -L-glutamate) and 9-b -D-ribofuranozilhypoxanthine.
DESCRIPTIONS
Transparent colorless or slightly greenish odorless liquid.
PHARMACOLOGICAL PROPERTIES
Pharmacotherapeutic group:
Hepatoprotective agent with immunomodulating and antiviral activity.
Pharmacodynamics:
Molixan® possesses unique biological and pharmacological effects due to the following:
Regulation of thiol-disulfide metabolism in hepatocytes and immune cells.
Regulation of endogenous production of cytokines by liver macrophages including IFN a and g determining the drug immunorehabilitating and antiviral activity.
Pronounced differentiated impact on the normal and virus-transformed cells.
Inhibition of ATP-ase/helicase activity of NS3 HCV.
Being the analogue of key cell metabolites the active principles of the composite therapeutics, Molixan®, have high bioavailability, therefore, being introduced into biological media they instantly translocate into target cells inducing cascade mechanism of biochemical reactions regulating cell metabolism, proliferation, differentiation and apoptosis forming a wide range of immunomodulating and hepatoprotective effects. The differentiated action on unimpaired hepatocytes and resident macrophages (stimulation of metabolism, proliferation, and differentiation) and virus-infected cells (induction of apoptosis mechanism including due to expression of FasAg-CD95+ and Ras-signaling and p53-dependent apoptotic pathways in the virus-infected hepatocytes) is the basis for the mechanisms inhibiting the HBV and HCV replicative activity.
The antiviral Molixan® efficacy on HVC is determined by its capacity to inhibit the NS3 HCV ATP-ase/helicase activity hindering chronization and facilitating the viral elimination.
Molixan® corrects the Th1/Th2 cytokine production ratio with the T-cell group with prevailing activation of Th1-cells due to endogenous production stimulation of IL-2 and IL-12 providing stable cell-mediated immune response including functional activity of resident liver macrophages (Kupffer's cells).
Thus, Molixan® possesses antiviral, immunomodulating and hepatoprotective (inhibition of post-hepatitis fibrogenesis) effects that determines its medical indications.
Pharmacokinetics:
The Molixan® substance is an organic salt where counter-ions are endogenous substances (oxidized glutathione and inosine). The natural origin of the drug determinates its metabolic particularities by cell enzyme systems. According to preclinical studies the Molixan® pharmacokinetics after intravenous dosing of 10 mg/kg is described using double-part model with the following indices (as per oxidized glutathione): maximal plasma concentration - 170-180 m g/ml; elimination constant - 0.085 min-1; bioavailability - 450-500 min.m g/ml; total clearance - 20 ml/kg/min; average retention rate - 6-8 min. Being a natural product having peptide and purine constituents Molixan® is metabolized in organs and tissues to amino acids and derivatives of purine bases and it is eliminated via kidneys.
MOLIXAN® ADMINISTRATION TO THE PATIENTS WITH VIRAL HEPATITIS B AND C ENSURES THE FOLLOWING:
Antiviral immunity stimulation and the HBV and HCV replicative activity inhibition due to induction of apoptosis in the virus-infected cells
Cytolytic syndrome cessation and reduction of pathologic morphological signs in liver
Normalization of serological and biochemical indices
Serum HBsAg persistency cessation
Prevailing activation of the T-cell immunity along with regulable stimulation of the resident macrophage functions
Regulation of serum levels of anti-inflammatory cytokines
Inhibition of liver fibrogenesis
INDICATIONS
Therapy
Acute and chronic viral hepatitis B, C and mixed forms
Drug-induced hepatitis (including cases after tuberculous and cancer chemotherapy)
Alcohol-induced liver disease
Toxic hepatitis
Fat liver degeneration of various origin
Prevention
Liver cirrhosis and hepatocellular carcinoma
CONTRAINDICATIONS
The drug introduction is contraindicated only in cases of individual intolerance.
ADVERSE EFFECTS
Adverse effects were not noted. However, individual drug intolerance is possible. In that case the drug should be canceled and consulting with an attending physician is necessary.
DRUG FORM
1% and 3% solution for injections in 1-ml and 2-ml ampoules. Packages - 5 or 10 ampoules
STORAGE CONDITIONS
The drug should be stored in a shadowed place at not higher than +250C.
The drug shall not be used after expiration date.
The drug should be stored in a place inaccessible for children.
SHELF LIFE
2 years.
MANUFACTURE DETAILS
Pharma BAM Spb, Ltd.
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
